GermanyGermany

Merck halts Stimuvax trials after encephalitis case

24.03.2010

Darmstadt – German Merck KGaA has suspended its clinical programme for the cancer vaccine Stimuvax, after a patient developed encephalitis in a Phase II trail in multiple myeloma. The company, which is developing the liposome encapsulated synthetic MUC1 peptide in programmes against solid cancers of epithelial origin (such as the lung cancer NSCLC or breast cancer), said it will now investigate the causes of the unintended adverse effect. The patient was randomized to an experimental arm of Stimuvax (BP1-7-KLH), in combination with an intensified schedule of low-dose cyclophosphamide, which is not used in the the other Stimuvax studies. Stimuvax, which mimicks the MUCIN 1 transmembrane protein overexpressed in many cancers, induces a strong CTL response upon vaccination. In Phase III studies, the vaccine which had been in-licenced from the Canadian company Biomira in 2006 (now Oncothyreon), prolonged overall survival of NSCLC patients from 13.3 to 30.6 months. Thus the drug, to be marketed by Merck in Europe and EMD Serono Inc in the US, was expected to become the next cancer blockbuster. Oncothyreon’s share were down by over 25% yesterday and analysts speculated that a coorelation between the drug and the adverse affect would affect Merck’s growth expectations. Merck said the action was a precautionary measure while investigating the cause of the adverse event. The suspension affects Merck’s Phase III clinical program, consisting of the non-small cell lung cancer (NSCLC) studies START with 1,300 patients and INSPIRE with additional 420 patients and the breast cancer study STRIDE with 900 volunteers, as well as the other recruiting studies.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/merck-halts-stimuvax-trials-after-encephalitis-case.html

Product of the week

Products

Events

All Events

Current issue

All issues